Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Carboplatin in First-Line Extensive Stage SCLC
NCT00305942Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2006
- Primary completion
- Apr 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan liposome in small cell lung cancer (SCLC), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 18 months. Started Mar 2006; status: completed.
02
Drugs
topotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00305942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305942.